Daiichi Sankyo nabs leukemia drugmaker Ambit in $410M deal

Astellas may not have wanted Ambit Biosciences ($AMBI) as a development partner, but fellow Japanese pharma Daiichi Sankyo wants it as an acquisition. Daiichi will snap up the once-dumped San Diego-based biotech for up to $410 billion in a move to beef up its oncology pipeline. With it comes quizartinib, a late-stage acute myeloid leukemia candidate. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.